Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis

Table 7 Comparison of biochemical parameters between patients remaining compensated and individuals progressing to decompensation during the follow-up period

Variables (mean ± SD)	Patients remaining compensated (n = 107)	Patients progressing to decompensation (n = 43)	P value1
AST (IU/L)	29.28 ± 8.55	32.50 ± 27.15	NS
ALT (IU/L)	50.13 ± 17.5	54.86 ± 31.4	NS
Bilirubin (µmol/L)	23.64 ± 4.74	32.97 ± 7.10	NS
PLT count (mm3)	183 ± 48.77	87.60 ± 28.15	< 0.0001
RDW-CV (%)	15.66 ± 3.53	34.41 ± 23.05	< 0.0001
RDW-SD (fL)	53.05 ± 8.91	64.30 ± 10.07	< 0.0001
Albumin (g/L)	35.02 ± 7.41	32.48 ± 1.54	NS
INR	1.26 ± 0.36	1.89 ± 0.27	NS
HOMA-IR	2.94 ± 1.57	3.66 ± 1.26	NS
Insulin (µu/mL)	11.50 ± 3.36	12.09 ± 2.98	NS
FPG (mg/dL)	121 ± 18.09	120.9 ± 16.07	NS
Total cholesterol (mg/dL)	185.2 ± 39.71	175.3 ± 54.09	NS
HDL (mg/dL)	43.23 ± 9.82	40.13 ± 9.97	NS
LDL (mg/dL)	125.9 ± 37.9	126.7 ± 44.51	NS
Tryglicerides (mg/dL)	145.8 ± 53.29	162.4 ± 82.99	NS
Creatinine (mg/dL)	1.13 ± 0.91	2.13 ± 1.07	0.02

¹Mann-Whitney U test.

Statistically significant differences (P < 0.05) are reported in bold. AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, PLT: Platelets count; CV: Coefficient variation; RDW: Red-cell distribution width; INR: International normalized ratio; HOMA-IR: homeostasis model assessment for insulin resistance; n.s.: Not statistically significant.